A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results

We conducted a phase Ib study to examine the safety of a combination of carbon-ion RT (CIRT) with durvalumab (MEDI4736; AstraZeneca) in patients with locally advanced cervical cancer. This was an open-label, single-arm study with a modified 3 + 3 design. Patients with newly diagnosed histologically...

Descripción completa

Detalles Bibliográficos
Autores principales: Okonogi, Noriyuki, Murata, Kazutoshi, Yamada, Shigeru, Habu, Yuji, Hori, Makoto, Kurokawa, Tomoya, Inaba, Yosuke, Fujiwara, Tadami, Fujii, Yasuhisa, Hanawa, Michiko, Kawasaki, Yohei, Hattori, Yoko, Suzuki, Kazuko, Tsuyuki, Kyoko, Wakatsuki, Masaru, Koto, Masashi, Hasegawa, Sumitaka, Ishikawa, Hitoshi, Hanaoka, Hideki, Shozu, Makio, Tsuji, Hiroshi, Usui, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342070/
https://www.ncbi.nlm.nih.gov/pubmed/37445743
http://dx.doi.org/10.3390/ijms241310565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342070/
https://www.ncbi.nlm.nih.gov/pubmed/37445743
http://dx.doi.org/10.3390/ijms241310565

Ejemplares similares